Oncternal (ONCT) Net earnings per share growth forecast for next year

Corporate company logo of Oncternal Therapeutics (ONCT)

EPS growth prospects for next year on the GURU.Markets terminal linear chart are based on Oncternal Therapeutics (ONCT) developing targeted therapies for rare leukemias, with the 0.00 parameter determining the metric's magnitude. However, the risk of late-stage trial failure and competition pose threats, while the closure of primary tests has led to asset mothballing and the consideration of the firm's liquidation.

Oncternal (ONCT): Net earnings per share growth forecast for next year from 07/04/2022 to 12/14/2024

Summary analytical data breakdowns for Oncternal (ONCT)

- share price and consensus valuation forecast:
Fundamental company analysis:Oncternal Therapeutics
Finished products of Oncternal Therapeutics Inc

This indicator measures the expected earnings per share (EPS) growth for the next period, reflecting the analysts' consensus forecast regarding the business's ability to scale profitability. In the context of developing targeted lymphoma therapies for Oncternal Therapeutics (ONCT), shifts in analysts' expectations for EPS n+1 growth demonstrate the impact of clinical successes on future capitalization, allowing for an assessment of the company's fundamental stability and asset quality.

Competitor analysis for Oncternal Therapeutics

INCY (incyte.com) - Earnings growth forecast for next year|Expected net earnings per share growth next year hutch-med.com HCM|Net earnings per share growth forecast for next year Nuvation Corp (NUVB)|DAWN - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Monopar Pharma MNPR|Inhibrx Corp - Net earnings per share growth forecast for next year|IMAB - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Fennec Pharmaceuticals|HRTX: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Nuvectis NVCT|Expected earnings per share growth for next year CHRS|Expected net earnings per share growth next year Corbus Pharmaceuticals CRBP|Expected earnings per share growth for next year CRDF (Cardiff Oncology Inc.)|BYSI (BeyondSpring) - Expected earnings per share trend next year|BioAtla - Expected earnings per share growth for next year|Projected earnings per share increase next year LIXT (Lixte Biotechnology Holdings, Inc.)|Citius Pharmaceuticals, Inc. - Earnings growth forecast for next year|Expected earnings per share trend next year CLRB (Cellectar)|BLRX: Earnings growth forecast for next year|Expected net earnings per share growth next year canfite.com (CANF)|Net earnings per share growth forecast for next year aprea.com|KZIA: Expected earnings per share trend next year|Earnings growth forecast for next year SLXN|Earnings growth forecast for next year NuCana PLC (NCNA)|Net earnings per share growth forecast for next year Chimerix, Inc CMRX|CYCC (Cyclacel) - Net earnings per share change forecast for next year|GTHX: Expected earnings per share growth for next year|Expected net earnings per share growth next year Kronos Bio Inc|Kintara Therapeutics Inc (KTRA) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year PRTG (Portage Biotech Corp)